Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events.
Petrosillo
N
N
Chinello
P
P
Proietti
M F
MF
Cecchini
L
L
Masala
M
M
Franchi
C
C
Venditti
M
M
Esposito
S
S
Nicastri
E
E
D000151:Acinetobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D040981:Acinetobacter baumannii / Q000187:drug effects; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D015780:Carbapenems / Q000494:pharmacology*; D003091:Colistin / Q000009:adverse effects / Q000627:therapeutic use; D016638:Critical Illness; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D012293:Rifampin; D003091:Colistin